Opendata, web and dolomites


Tomosynthesis is a low-dose alternate to has CT already transformed Breast Imaging, our vision is to reduce the costs, further enhance sensitivity and reduce dose, and transform portability.

Total Cost €


EC-Contrib. €






Project "Tomo-FPS" data sheet

The following table provides information about the project.

Adaptix Ltd 

Organization address
address: R1 Rutherford Appleton Laboratory
city: Harwell Campus
postcode: OX11 0QX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme /SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2015-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Adaptix Ltd UK (Harwell Campus) coordinator 50˙000.00


 Project objective

The power of 3D X-ray imaging in healthcare in the form of Computed Tomography (CT) is widely accepted, but despite the widespread availability of CT and Magnetic Resonance Imaging (MRI) it is still the basic 2D planar X-ray that constitutes the majority (circa 60%) of medical imaging studies worldwide. Planar X-ray continues to be the “workhorse of radiology” because of its availability, low cost and small system footprint (compared to MRI and CT); its speed of image acquisition and review (compared to all other modalities); its ability to visualize tissues like bone (unlike MRI and Ultrasound); its low radiation dose (unlike CT); and its consistency and objectivity of image acquisition (unlike Ultrasound).

Tomosynthesis, a method for performing high-resolution limited-angle tomography at low dose levels, has already transformed breast cancer screening and has demonstrated an ability to near-equal CT in identifying lung nodules symptomatic of lung cancer.

Our innovation is a Flat Panel X-ray Source (FPS) that allows tomosynthesis without any moving parts. This will reduce costs and enhance acquisition speed and allows the source to be closer to the subject, reducing power needs and further reducing cost.

Unlike current tomosynthesis devices that move the source in 1 dimension, a system using an FPS could vary emission in 2 dimensions which could enhance depth resolution and the ability to localise objects. This would enhance the ability to quantify features, including biomarkers of disease progression.

Adaptix will transform planar X-ray by giving it true 3D capability, making it safer by reducing dose (versus CT, and potentially versus planar X-ray), making the systems 50% cheaper than existing market offerings and reducing weight and size by 90%. By doing this we will be improving access to the world’s most important medical diagnostic device and radically changing a $5bn global market.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TOMO-FPS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TOMO-FPS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

BADGER (2017)

CalScreener® – an innovative device for Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time

Read More  

ABC-S (2018)

Acoustic Blood Cells Sorter

Read More  

SDS-OmiProbe (2017)

Revolutionary opto-biological methodology for aggressive HER2 cancer

Read More